FR22C1023I1 - ST-246 POLYMORPHIC FORM AND METHODS OF PREPARATION - Google Patents

ST-246 POLYMORPHIC FORM AND METHODS OF PREPARATION

Info

Publication number
FR22C1023I1
FR22C1023I1 FR22C1023C FR22C1023C FR22C1023I1 FR 22C1023 I1 FR22C1023 I1 FR 22C1023I1 FR 22C1023 C FR22C1023 C FR 22C1023C FR 22C1023 C FR22C1023 C FR 22C1023C FR 22C1023 I1 FR22C1023 I1 FR 22C1023I1
Authority
FR
France
Prior art keywords
preparation
methods
polymorphic form
polymorphic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1023C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siga Technologies Inc
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of FR22C1023I1 publication Critical patent/FR22C1023I1/en
Application granted granted Critical
Publication of FR22C1023I2 publication Critical patent/FR22C1023I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/72—4,7-Endo-alkylene-iso-indoles
    • C07D209/76—4,7-Endo-alkylene-iso-indoles with oxygen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
FR22C1023C 2010-03-23 2022-06-02 POLYMORPH FORM ST-246 AND PREPARATION PROCESSES Active FR22C1023I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31674710P 2010-03-23 2010-03-23
US37303110P 2010-08-12 2010-08-12
PCT/US2011/029576 WO2011119698A1 (en) 2010-03-23 2011-03-23 Polymorphic forms st-246 and methods of preparation

Publications (2)

Publication Number Publication Date
FR22C1023I1 true FR22C1023I1 (en) 2022-07-22
FR22C1023I2 FR22C1023I2 (en) 2024-02-16

Family

ID=44656766

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1023C Active FR22C1023I2 (en) 2010-03-23 2022-06-02 POLYMORPH FORM ST-246 AND PREPARATION PROCESSES

Country Status (20)

Country Link
US (7) US9339466B2 (en)
EP (1) EP2549871B1 (en)
JP (3) JP6018041B2 (en)
KR (6) KR20160062208A (en)
CN (4) CN103068232B (en)
AP (1) AP3221A (en)
AU (1) AU2011232551B2 (en)
BR (1) BR112012023743B1 (en)
CA (2) CA3030671A1 (en)
CL (1) CL2012002621A1 (en)
DK (1) DK2549871T3 (en)
FR (1) FR22C1023I2 (en)
IL (4) IL221991B (en)
MX (1) MX361428B (en)
NZ (1) NZ602578A (en)
PE (2) PE20130212A1 (en)
RU (2) RU2015146899A (en)
SG (2) SG184201A1 (en)
WO (1) WO2011119698A1 (en)
ZA (1) ZA201207141B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
KR20160062208A (en) * 2010-03-23 2016-06-01 시가 테크놀로지스, 인크. Polymorphic forms st-246 and methods of preparation
AU2013302764B2 (en) * 2012-08-16 2017-12-21 Siga Technologies, Inc. Methods of preparing Tecovirimat
CN105307636A (en) * 2013-07-19 2016-02-03 西佳技术公司 Amorphous tecovirimat preparation
EP3043793B1 (en) * 2013-11-19 2021-01-06 Siga Technologies Inc. Rehydration of micronized tecovirimat monohydrate
AU2015320358B2 (en) * 2014-09-26 2020-05-14 Millendo Therapeutics, Inc. Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto
EP3416637A4 (en) 2016-02-16 2019-11-06 Siga Technologies, Inc. St-246 ( tecovirimat monohydrate) suspension formulations
EP3605680A4 (en) 2017-03-31 2021-01-13 Osaka Gas Co., Ltd. Electrochemical element, electrochemical module, solid oxide fuel cell and production method
RU2716709C1 (en) * 2019-08-20 2020-03-16 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Oral dosage form of the preparation in capsules for treating and preventing orthopoxvirus-related diseases
WO2023080188A1 (en) * 2021-11-04 2023-05-11 興和株式会社 Encapsulated formulation
WO2023080189A1 (en) * 2021-11-04 2023-05-11 興和株式会社 Medicinal product

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670901A1 (en) * 1967-08-09 1971-03-18 Hoechst Ag Process for the preparation of benzenesulfonylureas
US4173646A (en) * 1974-10-04 1979-11-06 Merck & Co., Inc. Tricyclicdicarboximides
US4061763A (en) * 1975-05-09 1977-12-06 Merck & Co., Inc. Tricyclicdicarboximides
US5068356A (en) * 1990-02-20 1991-11-26 Atochem North America, Inc. Hindered phenolic n-(amido)imides
ZA939565B (en) 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
AU2256702A (en) 2000-12-01 2002-06-11 Kyowa Hakko Kogyo Kk Composition improved in solubility or oral absorbability
US6596771B2 (en) 2001-01-12 2003-07-22 Schering Corporation Drugs for treating viral infections
US6433016B1 (en) 2001-01-12 2002-08-13 Vassil Stefanov Georgiev Drugs for treating viral infections
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7687641B2 (en) * 2003-06-20 2010-03-30 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7737168B2 (en) 2003-06-20 2010-06-15 Siga Technologies, Inc. Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
AU2004249250C1 (en) * 2003-06-20 2012-04-12 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US20070122471A1 (en) 2003-12-25 2007-05-31 Takeda Pharmaceutical Company Limited Method of improving suitability for granulation
DK1838670T3 (en) * 2004-12-09 2010-03-01 Zach System Spa Process for the preparation of carvedilol and its enantiomers
US8642577B2 (en) * 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
AP2267A (en) 2006-03-02 2011-08-02 Siga Technologies Inc Antiviral drugs for treatment of arenavirus infection.
EP3006425A1 (en) 2007-04-23 2016-04-13 Siga Technologies, Inc. Pharmaceutical composition for use in the treatment and prevention of orthopoxvirus infections and associated diseases
CN101445478B (en) * 2008-08-22 2011-04-06 中国人民解放军军事医学科学院生物工程研究所 Compound ST-246 containing a crystal water, crystal thereof and preparation method thereof
RU2412160C1 (en) * 2009-09-25 2011-02-20 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) 7-[n'-(4-trifluoromethylbenzolyl)-hydrazinocarbonyl]-tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic acid, having antiviral activity
KR20160062208A (en) * 2010-03-23 2016-06-01 시가 테크놀로지스, 인크. Polymorphic forms st-246 and methods of preparation

Also Published As

Publication number Publication date
US20240156782A1 (en) 2024-05-16
RU2015146899A (en) 2019-01-11
MX361428B (en) 2018-12-06
KR20160028489A (en) 2016-03-11
US9744154B2 (en) 2017-08-29
US10045964B2 (en) 2018-08-14
CA2793533C (en) 2019-02-26
CN103068232B (en) 2015-08-26
KR20130018271A (en) 2013-02-20
CN105111131A (en) 2015-12-02
WO2011119698A9 (en) 2013-01-31
SG184201A1 (en) 2012-10-30
AU2011232551B2 (en) 2014-11-13
FR22C1023I2 (en) 2024-02-16
US20180193308A1 (en) 2018-07-12
US11890270B2 (en) 2024-02-06
CA2793533A1 (en) 2011-09-29
US20210137885A1 (en) 2021-05-13
PE20170944A1 (en) 2017-07-13
AP3221A (en) 2015-04-30
EP2549871B1 (en) 2018-08-22
IL258239A (en) 2018-05-31
CL2012002621A1 (en) 2013-10-11
US10406137B2 (en) 2019-09-10
US20110236434A1 (en) 2011-09-29
KR20150092354A (en) 2015-08-12
WO2011119698A1 (en) 2011-09-29
RU2012144818A (en) 2014-04-27
EP2549871A4 (en) 2016-03-09
EP2549871A1 (en) 2013-01-30
US10933050B2 (en) 2021-03-02
MX2012010859A (en) 2013-04-29
US20160107993A1 (en) 2016-04-21
JP2016040323A (en) 2016-03-24
CN103068232A (en) 2013-04-24
US20180311213A1 (en) 2018-11-01
RU2578606C2 (en) 2016-03-27
IL221991B (en) 2019-06-30
US20190343799A1 (en) 2019-11-14
CA3030671A1 (en) 2011-09-29
SG10201501936PA (en) 2015-05-28
IL241731A0 (en) 2015-11-30
JP2013522371A (en) 2013-06-13
AP2012006514A0 (en) 2012-10-31
BR112012023743B1 (en) 2020-02-18
JP2018012735A (en) 2018-01-25
JP6018041B2 (en) 2016-11-02
IL241730A0 (en) 2015-11-30
CN105111130A (en) 2015-12-02
CN105175311A (en) 2015-12-23
AU2011232551A1 (en) 2012-10-18
KR20150011016A (en) 2015-01-29
KR20160062208A (en) 2016-06-01
DK2549871T3 (en) 2018-12-10
PE20130212A1 (en) 2013-03-09
BR112012023743A2 (en) 2015-09-15
ZA201207141B (en) 2016-06-29
KR20170102070A (en) 2017-09-06
US9339466B2 (en) 2016-05-17
NZ602578A (en) 2014-08-29

Similar Documents

Publication Publication Date Title
FR22C1023I1 (en) ST-246 POLYMORPHIC FORM AND METHODS OF PREPARATION
IL226477A (en) Salts and polymorphic forms of afatinib
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
BR112012017441A2 (en) compounds and methods
CO6960555A2 (en) Preparation procedure of substituted 5-fluoro-1h-pyrazolopyridines
ZA201303813B (en) Methods of treatment using lipid compounds
IT1400092B1 (en) CRIOCONSERVATION METHOD OF DENTAL PULP
CU24148B1 (en) AGOMELATIN INTERMEDIATES AND METHOD OF PREPARATION OF THESE
BR112013014435A2 (en) hppe member and method of preparing an hppe member
CO6990730A2 (en) Microbicidal composition and process of obtaining it
IT1402029B1 (en) PROCEDURE FOR THE PREPARATION OF ERLOTINIB
ITBS20100012A1 (en) PROCEDURE FOR THE PREPARATION OF FLUAZINAM
EP2588428A4 (en) Methods of kinome analysis
BR112013014291A2 (en) liposomal formulation of calcetrapib
IT1400937B1 (en) PROCEDURE FOR OBTAINING ANALLERGIC PROPOLIS
FR2955473B1 (en) STRUCTURE OF DISPLAY
BR112012029669A2 (en) composition and method
FR2956419B1 (en) ELEMENTS OF CONSTRUCTION CALORIFUGES
FR2999175B1 (en) METHOD OF ISOLATING DIAMONDOIDES
BR112013013441A2 (en) adhesive-ironing composition and related methods
FI20105265A0 (en) Condenser and method of preparation
EP2647632A4 (en) Preparation method of a-imatinib mesylate
DE112011102778A5 (en) Magnetovariational procedure
FI20100388A0 (en) method of culture